Compare Amgen, Inc. (AMGN) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Nuscale Power Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Nuscale Power Corporation trades at $8.91 (market cap $3.13B). The key difference: Amgen, Inc. is far larger — about 62.7× Nuscale Power Corporation's market cap, and Amgen, Inc. pays a 2.77% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| AMGN | SMR | |
|---|---|---|
Market Cap | $196.12B | $3.13B |
Sector | Health | Utilities |
52-Week High | $388.16 | $53.43 |
52-Week Low | $271.18 | $8.76 |
Enterprise Value | $241.41B | $2.24B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NuScale Power (SMR) trades at $9.03, showing no daily change. The stock exhibits a bearish technical trend with significant negative profitability metrics, including a net income margin of -2,066.55% and consecutive quarterly earnings misses. Despite these challenges, analyst consensus remains optimistic with a $13.00 price target, citing the company's first-mover advantage in small modular nuclear reactors and potential long-term growth tied to AI-driven power demand.
The outlook for SMR balances high-risk, high-reward potential. Opportunities include certified SMR technology and strategic partnerships, but risks are substantial: persistent operating losses, negative cash flow from operations, and uncertainty around commercial reactor sales. Investors face volatility with the stock near 52-week lows, requiring careful assessment of execution capability versus speculative growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
